


# Fluent Drug Development

TAP Pharmaceutical Products R&D



TAP Pharmaceutical Products Inc.  
675 North Field Drive  
Lake Forest, Illinois 60045

[www.tap.com](http://www.tap.com)



TAP is a **Strong** company in big ways.

Stable. Connected. Enduring. TAP is among the biggest and most dynamic pharmaceutical companies. What started in 1977 as a joint venture between Japan's Takeda Chemical Industries, Ltd. and U.S.-based Abbott Laboratories has become a powerful drug development force, with two blockbuster products, annual sales around \$4 billion, and nearly 3,000 employees.

TAP is an **Agile** company that makes smart decisions quickly.

TAP has the spirit of a small company. Energetic. Entrepreneurial. We innovate and collaborate to drive growth that reflects the character and creativity of the many faces who make it happen.

These attributes converge to fuel a critical TAP asset: our **pipeline**, where the synchrony of people, process, and gigabytes results in the fast-track evolution of health care. This is fluent drug development.

Optimizing technology makes our pipeline **Productive**.


e-R&D is technology-assisted product development that includes communication and data management via four tech systems that are thoroughly explored, then pushed to the point of optimization. We call our process SECURE™ (Safely Examine and Create Universal Records Electronically).

Harriet Glassman, M.S.  
Director, Project Management

Harriet's team of project managers uses e-R&D technology to feed fertile minds with information that continually redefines our pace – and ultimately, the productivity of our pipeline.

The evolution starts here, in R&D, with the energy of innovation and speed of high-tech solutions lighting the way for novel therapeutic concepts to become blockbuster reality in the areas of women's health, men's health, and gastroenterology.

**Inquisitive** minds use technology to erase boundaries, explore data, gain access to novel leads.



Joshua Owolabi, Ph.D.  
Assistant Director of the  
Virtual Discovery Group

Sheila Cross, Ph.D.  
Director of the  
Virtual Discovery Group

Does this science make sense?  
That's just one of the thousands  
of questions Sheila and Joshua  
ask of the data while searching  
for drug leads and chemical  
entities to load the pipeline.

Before TAP commits capital – intellectual and monetary – to technical assessment, the Virtual Discovery Group turns the data upside down to determine the value and risks of forward motion.



Steve Elrod, Ph.D., D.A.B.T.  
Director of Scientific Affairs


Designs for pre-clinical studies  
and drug scale-up emerge from  
minds like Steve's – people with  
expertise in analytical science,  
formulation, metabolism,  
pharmacology, pharmacokinetics,  
toxicology, and pathology.

“Calculated excitement” is the mood as the drug enters the pipeline and Scientific Affairs begins to define its benefits and limitations.

Here, internal expertise and high-tech process combine with external capacity for a flexible system that characterizes and

Invented inside, **Ingenious** designs for clinical studies and scale-up.

Our strategies, like our people, are **Dynamic**, advancing with knowledge gained.



Denise Moyse, M.S., M.B.A.  
Assistant Director of  
Project Management

Project managers like Denise  
create connection and balance  
between individuals, scientific  
and regulatory requirements,  
timelines, and budgets.

The rewards of the journey are felt all along the critical pathway to market and beyond, because our pipeline is also a path to our most valued achievement: productive relationships.



E. David Ballard, II, M.D.  
Therapeutic Area Head,  
Gastroenterology/Internal Medicine

David leads a group of insightful  
clinical experts who define, shape,  
and re-shape the drug development  
strategy that will take a product  
to market first.

Within the pipeline is a fluent environment where science and business collaborate and evolving clinical data initiates scenario plans created weeks, months ago. Through experience, we expect the unexpected. With insight, we adapt.

interrogates a drug, minimizing timelines without compromising science.

**Interactive** people from around the globe connect, create, communicate.

**Smart** use of technology means our blockbusters can also be clockbusters.

Nancy Siepman, Ph.D.  
Director of Statistics  
and Study Programming

e-R&D people like Nancy are vigilant, testing every piece of code more than once and educating data gatherers how to capture and tag regulatory documentation. Even in e-R&D, a perfect submission is more about people than technology.

Open systems mean we can – and do – submit electronically for all new drugs, leaving shelves empty and minds free to execute in ether-land.

After product launch, our people, process, and technologies continue on, enhanced and

We are **Motivated** by the meaning.

A philosophy that elevates people and exploits technology moves us to perpetual discovery of novel therapies and new indications so we can reach more patients and strengthen our connection to care.



This is Laurie, enjoying time with her son. She feels better because of a TAP product that treated her endometriosis.

Strong. Agile. Productive. Inquisitive.

Ingenious. Interactive. Dynamic.

Smart. Motivated... **Connected.**

Like the 400+ individuals who work in TAP R&D, the words health and care have separate and unique identities, each highly valued. But brought together in a fluent drug development process, they create a momentum, scientific vision, and humanitarian value beyond words.

Fluent Drug Development. Connected to Care.  
TAP Pharmaceutical Products Inc.

evolved by prior experience. This is fluent drug development.